Venus Remedies gets additional US patent nod for Vancoplus

Drug firm Venus Remedies today received additional patent approval from United States Patent and Trademark Office (USPTO) for its product 'Vancoplus', used for treating bacterial infections.

"Venus Remedies already has product patent for Vancoplus from USPTO. This additional patent with broader coverage for use and method of treatment will be beneficial for the company," Venus Remedies said in a filing to BSE.

The patent is valid till 2032 and the company has already initiated pre-Investigational New Drug meeting with US health regulator, it added.

Vancoplus is a highly effective remedy to control Methicillin-resistant Staphylococcus aureus (MRSA), VRSA (Vancomycin Resistance Staphylococcus aureus) and other bacterial infections.

Global anti-bacterial market is slated to reach around USD 64 billion by 2018, Venus Remedies said.

Shares of Venus Remedies were trading at Rs 302.80 per scrip in the afternoon trade on BSE, up 0.26 per cent from its previous close.

EDITORIAL OF THE DAY

  • Enhanced allocations are needed for research to ‘Make in India’ for India

    Even as India flaunts its ambitious ‘Make in India’ initiative from February 13, it spurs several questions.

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Urs Schoettli

The importance of Indonesia

A few weeks ago, the wo­rld was shocked by a ...

Rajgopal Nidamboor

Try to awaken the archaeologist within

Our mind is far ahead of René Descartes’ famous maxim, ...

Bubbles Sabharwal

Social media versus real life

It’s amazing how social media brings out the best side ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture